<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377168</url>
  </required_header>
  <id_info>
    <org_study_id>XR-NTX ETOH</org_study_id>
    <nct_id>NCT01377168</nct_id>
  </id_info>
  <brief_title>Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder</brief_title>
  <official_title>Oral Naltrexone for Improved Medication Compliance Among HIV-infected Men With Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociaci贸n Civil Impacta Salud y Educaci贸n, Peru</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will recruit 159 HIV-infected men with alcohol use disorders (AUDs). Men will be
      randomized to receive either oral naltrexone for the treatment of alcohol use disorder or
      placebo. Men with acute, recent or established HIV infection will receive antiretroviral
      treatment (ART) and be randomized to oral naltrexone or placebo. The purpose of this study is
      to see whether use of oral naltrexone improves medication compliance, and therefore HIV viral
      load suppression, among men with alcohol use disorder. The study will also assess the impact
      of oral naltrexone on alcohol use behaviors in this population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Viral Load Suppression</measure>
    <time_frame>6 months</time_frame>
    <description>The primary outcome will be the proportion with a VL&lt;400 copies/mL at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ART Compliance and Alcohol Use Behavior</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary HIV outcomes will include time to ART initiation, retention on ART over 6 months, and HIV sexual risk behaviors. Alcohol use outcomes include the following: 1) Time to relapse to heavy drinking (for men defined as &gt;5 drinks/drinking day); 2) percent of days drinking (PDD) over the six-month examination period; 3) percent of days abstinent (PDA) over the six month examination period; and 4) alcohol craving using the Obsessive Compulsive Drinking Scale where a mean change in total score will be assessed and compared between treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>HIV</condition>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily oral naltrexone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral naltrexone</intervention_name>
    <arm_group_label>NTX</arm_group_label>
    <other_name>Nalerona</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for alcohol dependence or problem drinking.

          -  Age 18 years and older

          -  Confirmed HIV infection, either through positive HIV antibody or detectable HIV-1 RNA
             level.

          -  No participation in pharmacotherapy trial in the previous 30 days

          -  Not pregnant

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Verbally or physically threatening to research staff

          -  Unable to communicate in Spanish

          -  Pending trials for a felony

          -  Childs-Pugh Class C Cirrhosis

          -  Grade 3 Hepatitis (LFTs &gt; 5X normal)

          -  Receiving opioid prescription narcotics or has pain syndrome necessitating future use
             of opioid prescription narcotics.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Duerr, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick Altice, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociaci贸n Civil Impacta Salud y Educaci贸n</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Ann C Duerr</investigator_full_name>
    <investigator_title>Member</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

